HIV-1 genetic diversity and drug resistance among senegalese patients in the public health system

Journal of Clinical Microbiology

Volumn 51, Issue 2, 2013, Pages 578-584

  Thiam, Moussa ^a   Diop Ndiaye, Halimatou ^a   Diouf, Aminata Diaw ^a   Vidal, Nicole ^b   Ndiaye, Ousseynou ^a   Ndiaye, Ibrahima ^c   Ngom Gueye, Ndeye Fatou ^d   Diallo, Sada ^a   Diongue, Oumy Diop ^a   Camara, Makhtar ^a   Seck, Abdoulaye ^a   Mboup, Souleymane ^a   Toure Kane, Coumba ^a  

^a Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d Centre Hospitalier Universitaire Dakar   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SENEGAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; PUBLIC HEALTH; SENEGAL; VIRAL LOAD; YOUNG ADULT;

EID: 84873025208     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02452-12     Document Type: Article

References (40)

1. Diop-Ndiaye H, Toure-Kane C, Leye N, Ngom-Gueye NF, Montavon C, Peeters M, Mboup S. 2010. Antiretroviral drug resistance mutations in antiretroviral-naive patients from Senegal. AIDS Res. Hum. Retroviruses 26:1133-1138.
2. Toure-Kane C, Montavon C, Faye MA, Gueye PM, Sow PS, Ndoye I, Gaye-Diallo A, Delaporte E, Peeters M, Mboup S. 2000. Identification of all HIV type 1 groupMsubtypes in Senegal, a country with low and stable seroprevalence. AIDS Res. Hum. Retroviruses 16:603- 609.
3. Hamel DJ, Sankalé JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup S, Kanki PJ. 2007. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res. Hum. Retroviruses 23:1189 -1196.
4. Ndiaye HD, Toure-Kane C, Vidal N, Niama FR, Niang-Diallo PA, Dièye T, Gaye-Diallo A, Wade AS, Peeters M, Mboup S. 2009. Surprisingly high prevalence of subtype C and specific HIV-1 subtype/CRF distribution in men having sex with men in Senegal. J. Acquir. Immune Defic. Syndr. 52:249 -252.
5. Tournoud M, Etard JF, Ecochard R, DeGruttola V. 2010. Adherence to antiretroviral therapy, virological response, and time to resistance in the Dakar cohort. Stat. Med. 29:14 -32.
6. Laurent C, Diakhaté N, Gueye NF, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E. 2002. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16: 1363-1370.
7. World Health Organization. 2010. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. World Health Organization, Geneva, Switzerland. http://www.who.int/ hiv/pub/arv/adult2010/en/.
8. Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E. 2003. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 17:S31-38.
9. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte A, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD, EuroSIDA Study Group. 2009. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J. Infect. Dis. 200:687- 697.
10. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, Nguyen DP, Katzenstein D, Fessel WJ. 2004. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18: 1503-1511.
11. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J. 2009. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23:1127-1134.
12. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhaté N, Touré Kane NC, Lanièce I, Ndir A, Vergne L, Ndoye I, Mboup S, Sow PS, Delaporte E, ANRS 1215/1290 Study Group. 2005. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1- infected adults. J. Acquir. Immune Defic. Syndr. 38:14 -17.
13. Wallis C, Mellors J, Venter W, Sanne I, Stevens W. 2009. Protease inhibitor resistance is uncommon in patients on failing second-line lopinavir/r-containing regimen in South Africa. Antivir. Ther. 14(Suppl 1): A183.
14. Gouy M, Guindon S, Gascuel O. 2010. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 27:221-224.
15. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure- Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E. 2000. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatmentnaive patients. J. Clin. Microbiol. 38:3919 -3925.
16. Peeters M, Aghokeng AF, Delaporte E. 2010. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin. Microbiol. Infect. 16:1525-1531.
17. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndèye GF, Sow PS, Ndèye KC, Ecochard R, Delaporte E, ANRS 1215 Study Group. 2010. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect. Dis. 10:179.
18. Diouara AAM, Kebe K, Diop-Ndiaye H, Thiam M, Leye N, Diallo S, Thiackpe E, Diallo A, Faye M, Sakine M, Ouattara B, Diouf S, Toure- Kane C, Mboup S. 2011. Apport du papier buvard dans le génotypage du VIH-1 en milieu décentralisé au Senegal, WEAA0504. 16ème Conférence Internationale sur le Sida et les IST en Afrique, Addis Abeba, Ethiopie.
19. Péré H, Charpentier C, Mbelesso P, Dandy M, Matta M, Moussa S, De Dieu Longo J, Grésenguet G, Abraham B, Bélec L. 2012. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic. AIDS Res. Hum. Retroviruses 28:315-323.
20. El-Khatib Z, Ekström AM, Ledwaba J, Mohapi L, Laher F, Karstaedt K, Charalambous S, Petzold M, Katzenstein K, Lynn M. 2010. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 24:1679 -1687.
21. Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, Koulla-Shiro S, Mpoudi-Ngole E, Peeters M, Delaporte E. 2009. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization(WHO)public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin. Infect. Dis. 48: 1318-1322.
22. Long L, Fox M, Sanne I, Rosen S. 2010. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 24:915-919.
23. ART-LIC of leDEA Study Group, Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, Nash D, Jahn A, MacPhail P, Lüthy R, Wood R, Egger M. 2009. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 23:1867-1874.
24. Price M, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, Sanders EJ, Bekker LG, Twesigye R, Hunter E, Kaleebu P, Kayitenkore K, Allen S, Ruzagira E, Mwangome M, Mutua G, Amornkul PN, Stevens G, Pond SL, Schaefer M, Papathanasopoulos MA, Stevens W, Gilmour J, IAVI Early Infection Cohort Study Group. 2011. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res. Hum. Retroviruses 27:5-12.
25. Phillips A, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. 2008. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371:1443-1451.
26. Brenner BG. 2007. Resistance and viral subtypes: how important are the differences and why do they occur? Curr. Opin. HIV AIDS 2:94 -102.
27. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. 2010. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J. Acquir. Immune Defic. Syndr. 53:480-484.
28. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, Carpenter S, Giddy J, Ross D, Holst H, Losina E, Walker BD, Kuritzkes DR, South Africa Resistance Cohort Study Team. 2008. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin. Infect. Dis. 46:1589 -1597.
29. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2002. The M184V mutation reduces the selective excision of zidovudine 5-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 76:3248 -3256.
30. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S. 2000. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS 14:781-789.
31. Larder BA, Kemp SD, Harrigan PR. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
32. Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S, CNA3003 International Study Team. 2002. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antivir. Ther. 7:43-51.
33. Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menéndez-Arias L, Martínez MA, Martinez-Picado J. 2004. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 326:103-112.
34. Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M. 2002. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J. Infect. Dis. 185:898 -904.
35. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. 2003. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis. 188: 992-1000.
36. Casado JL, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, Arnó A, Garcia-Arata I, Bloor S, Bonjoch A, Blazquez J, Clotet B, Larder B. 2000. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 14:F1-F7.
37. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999 -5008.
38. Scherrer AU, Hasse B, von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Bucher HC, Ledergerber B, Günthard HF. 2009. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Med. 10:647- 656.
39. Adlington R, Richens J, Shahmanesh M. 2009. First-line antiretroviral therapy in resource-limited settings: time to reconsider? J. Infect. Dis. 199:1407-1408.
40. Young TP, Parkin NT, Stawiski E, Pilot-Matias T, Trinh R, Kempf DJ, Norton M. 2010. Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrob. Agents Chemother. 54:4903- 4906.